SBC Medical Group Holdings, Inc. (SBC)
NASDAQIndustrialsConsulting ServicesSnapshot 2026-09-04
$4.12-3.74%
Close 2026-09-04 · 1-day change
NASDAQIndustrialsConsulting ServicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Maintain positive net income trajectory: EPS $0.10 vs $0.12 consensus (-16.7%).
SBC is expanding into the U.S. medical aesthetics market. It has a $20 million share buyback program. The company maintains a positive net income trajectory with $11.3M in Q1 2026. The stock trades cheaply with a PE of 7.6 versus peers at 27.
SBC's recent EPS guidance is soft at $0.50 for 2025 versus actual $0.14. Net income declined from $14.2M to $11.3M in recent quarters. The stock has sold off 35% from highs and faces sector headwinds.
The price is about 56% below our fair value near $7. Analysts expect roughly 10% revenue growth. The market prices in a cautious outlook reflecting recent softness and risks.
Breaks if: Net income falls below $8M in any quarter in 2026
Breaks if: Buyback program not executed or materially delayed by end 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a growth opportunity with a focus on enhancing services through AI and expanding its brand strategy. The current thesis state is intact, supported by strong recent financial performance despite some risks.
The market currently prices SBC as cheap compared to its peers, reflecting a significant expectations gap. This suggests that while there is some fragility in execution quality, the stock is not overly punished for its recent challenges.
Fundamentals are likely to remain strong in the near term, driven by management's focus on growth and disciplined investment. However, there is a notable risk of earnings misses given the company's recent history and the high-risk environment.
The future performance of SBC will depend on its ability to maintain growth momentum and avoid further earnings misses. Additionally, the performance of sector bellwethers like EFX, BAH, and FCN will be critical in determining the overall sector momentum.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company reported strong revenue growth. Net income rose 335% year-over-year. This suggests better demand and margins. However, earnings per share missed estimates by $0.02. This could pressure the company's net income trajectory.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: No meaningful U.S. market entry or partnerships by end 2026
Over the next 1 to 3 years, SBC's prospects will rely on effective execution of its growth strategies and external market conditions. Not investment advice.